前生物技术高管George Tidmarsh将领导FDA关键药物中心

2025-07-21 21:22

The U.S. FDA has named George Tidmarsh, a former biotech executive and adjunct professor at Stanford Medical School, to head its Center for Drug Evaluation and Research.
He replaces Patrizia Cavazzoni, who resigned on January 18.
Tidmarsh received his M.D. and Ph.D. -- in cancer biology -- from Stanford University. He also completed his pediatrics residency, as well as speciality training in pediatric oncology and neonatology at the university.
He is also founding co-director of Stanford’s Master of Translational Research and Applied Medicine (M-TRAM) program.
Tidmarsh founded and was CEO of Horizon Pharma, which was sold to Amgen (NASDAQ:AMGN) in 2022 for $28B.
He has also held executive or senior positions at La Jolla Pharmaceutical Co., Threshold Pharmaceuticals, Coulter Pharmaceutical (eventually acquired by GSK), and SEQUUS Pharmaceuticals (acquired by Johnson & Johnson).
Tidmarsh has overseen the development of seven FDA-approved drugs.

More on pharma companies